Other News To Note
• Durata Therapeutics Inc., of Morristown, N.J., reported in vitro data that could help support a clinical program testing antibiotic candidate dalbavancin in pneumonia. In the study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin. Results were presented at IDWeek in San Diego.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.